Profile photo Marc Bonten

Marc Bonten

Full Professor

Strategic program(s):

Biography

Marc Bonten earned his MD (1991) and PhD (“the role of colonization of the upper intestinal tract in the pathogenesis of ventilator-associated pneumonia, 1994) at the Maastricht University Medical School, the Netherlands. He registered as internist in 2000, as infectious disease specialist in 2002 and as clinical microbiologist in 2008, all at the University Medical Center Utrecht, the Netherlands. From 2008 till March 2021 he was head of the Department of Medical Microbiology. Since 2003 he is head of the research group of Infectious Disease Epidemiology of the Julius Center of Health Sciences and Primary Care and professor of molecular epidemiology of infectious diseases. He has been a principal investigator in many large scale epidemiologic studies and investigator-initiated randomized trials of prevention and treatment of infectious diseases. His experience covers the full range of epidemiologic study designs including clinical trials, cohorts, case-control studies and mathematical modelling to study antibiotic resistance and infection prevention. Specific research interests include the epidemiology of antibiotic-resistant bacteria such as VRE, MRSA and MDR Enterobacteriaceae, selective decontamination in intensive care unit patients, prevention of ventilator-associated pneumonia, treatment of community-acquired pneumonia, and prevention and treatment of community-acquired pneumonia, including COVID-19.

He is chairman of the strategic research program Infection & Immunity at the UMC Utrecht. (2017-)

Coordinator of the H2020-funded project ECRAID-Base (March 2021-) and Chief Executive Officer of the ECRAID foundation (Jan 2022-)

Member of the Koninklijke Nederlandse Academie voor Wetenschappen en Kunsten (Royal Academy of Sciences and Art) (April 2021-)

Research groups

Epidemiology and clinical trials in infectious diseases

Research aim

To improve prevention, diagnosis and treatment of infectious diseases and to establish an international research infrastructure for a rapid scientific response in the face of a new infectious disease threat.
Go to group

Epidemiology of sepsis & inflammation in critically ill patients

Research aim

We design and conduct clinical epidemiological research focused on risk stratification, early diagnosis, and novel treatment of critically ill patients with severe infections.
Go to group

Recent publications

The Plasma Lipidomic Landscape in Patients with Sepsis due to Community-acquired Pneumonia Osoul Chouchane, Alex R Schuurman, Tom D Y Reijnders, Hessel Peters-Sengers, Joe M Butler, Fabrice Uhel, Marcus J Schultz, Marc J Bonten, Olaf L Cremer, Carolyn S Calfee, Michael A Matthay, Raymond J Langley, Narges Alipanah-Lechner, Stephen F Kingsmore, Angela Rogers, Michel van Weeghel, Frédéric M Vaz, Tom van der Poll
American Journal of Respiratory and Critical Care Medicine, 2024, vol. 209, p.973-986
Efficacy and safety of an early oral switch in low-risk Staphylococcus aureus bloodstream infection (SABATO) Achim J. Kaasch, Luis Eduardo López-Cortés, Jesús Rodríguez-Baño, José Miguel Cisneros, M. Dolores Navarro, Gerd Fätkenheuer, Norma Jung, Siegbert Rieg, Raphaël Lepeule, Laetitia Coutte, Louis Bernard, Adrien Lemaignen, Katrin Kösters, Colin R. MacKenzie, Alex Soriano, Stefan Hagel, Bruno Fantin, Matthieu Lafaurie, Jean Philippe Talarmin, Aurélien Dinh, Thomas Guimard, David Boutoille, Tobias Welte, Stefan Reuter, Jan Kluytmans, Maria Luisa Martin, Emmanuel Forestier, Hartmut Stocker, Virginie Vitrat, Pierre Tattevin, Anna Rommerskirchen, Marion Noret, Anne Adams, Winfried V. Kern, Martin Hellmich, Harald Seifert, Adoración Valiente, Marina de Cueto, Ángel Rodríguez, José Molina, Julia Fischer, Gregor Paul, Sébastien Gallien, Vincent Fihman, Marion Lacasse, Francois Coustillères, Christian Becker, André Fuchs, Laura Morata, Marc J.M. Bonten,
The Lancet Infectious Diseases, 2024, vol. 24, p.523-534
Feasibility of tracking invasive Escherichia coli disease among older adults in a community setting Joachim Doua, Miquel Ekkelenkamp, Theo Verheij, Oscar Go, Stephen Ruhmel, Kimberly Leathers, Bart Spiessens, Sanne van Rooij, Vance G Fowler, Jeroen Geurtsen, Rowena Dolor, Michal Sarnecki, Ranee Chatterjee, Jan Poolman, Marc Bonten,
European Journal of Clinical Microbiology & Infectious Diseases, 2024, vol. 43, p.541-550
Biomarker guided antibiotic stewardship in community acquired pneumonia Ruud Duijkers, Hendrik J. Prins, Martijn Kross, Dominic Snijders, Jan W.K. van den Berg, Gwendolyn M. Werkman, Nynke van der Veen, Marianne Schoorl, Marc J.M. Bonten, Cornelis H. van Werkhoven, Wim G. Boersma
PLoS ONE, 2024, vol. 19, p.e0307193
Specific and off-target immune responses following COVID-19 vaccination with ChAdOx1-S and BNT162b2 vaccines—an exploratory sub-study of the BRACE trial Nicole Messina, Susie Germano, Rebecca McElroy, Rhian Bonnici, Branka Grubor-Bauk, David J. Lynn, Ellie McDonald, Suellen Nicholson, Kirsten Perrett, Laure Pittet, Rajeev Rudraraju, Natalie E. Stevens, Kanta Subbarao, Nigel Curtis, Andrew Davidson, Kaya Gardiner, Amanda Gwee, Tenaya Jamieson, Nicole Messina, Thilanka Morawakage, Susan Perlen, Kirsten Perrett, Laure Pittet, Amber Sastry, Jia Wei Teo, Francesca Orsini, Katherine Lee, Cecilia Moore, Suzanna Vidmar, Rashida Ali, Ross Dunn, Peta Edler, Grace Gell, Casey Goodall, Richard Hall, Ann Krastev, Nathan La, Nick McPhate, Thao Nguyen, Jack Ren, Luke Stevens, Ahmed Alamrousi, Thanh Dang, Jenny Hua, Marc Bonten, Axel Janssen, Cristina Prat-Aymerich, Darren Troeman, Nienke Paternotte, Bob Meek,
EBioMedicine, 2024, vol. 103, p.1-16
Estimation of introduction and transmission rates of SARS-CoV-2 in a prospective household study Michiel van Boven, Christiaan H van Dorp, Ilse Westerhof, Vincent Jaddoe, Valerie Heuvelman, Liesbeth Duijts, Elandri Fourie, Judith Sluiter-Post, Marlies A van Houten, Paul Badoux, Sjoerd Euser, Bjorn Herpers, Dirk Eggink, Marieke de Hoog, Trisja Boom, Joanne Wildenbeest, Louis Bont, Ganna Rozhnova, Marc J Bonten, Mirjam E Kretzschmar, Patricia Bruijning-Verhagen
PLoS Computational Biology, 2024, vol. 20

Fellowships & Awards

2023: SWAB award 2023

2021: Tales of the unexpected in antimicrobial resistance

2018: Deutsche Gesellschaft fur Hygiene und Mikrobiologie: DGHM lecture 2018

2017: Honorary Fellowship of the RCPI

2015: ESCMID award for excellence in Clinical microbiology and Infectious Diseases 2015

2015: Promotor of the year, 2015

2006: Bacteriën met wiskunde te lijf

External positions

CEO - Clinical trials - Ecraid

Consultancy, assisteren bij het identificeren van geschikte studie lokaties voor fase3 studie - Werkzaamheden in kader van mijn rol als CEO Ecraid - Janssen Research

Via Ecraid, identificeren van geschikte klinieken voor deelname aan wetenschappelijk onderzoek - CEO van Ecraid - Spherecytes

Wetenschappelijk advies - Expertisegebied - Pherecydes Pharma

Scientific Advisor Ensovibep - Expertise - Novartis

Member Scientific Advisory Board - Scientific evaluation of GRADP-funded research projects - GARDP

Independent Data Monitoring Committee of the PSK008 and PSK009 studies on pneumococcal vaccination. - expertise - Sanofi Pasteur

Chair of international study steering committee E.mbrace study - Expertise area - Janssen Vaccines and Prevention BV